Johnson & Johnson $JNJ Stock: QV Investors Inc. Reduces Holdings

QV Investors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 15.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 21,920 shares of the company’s stock after selling 3,960 shares during the period. QV Investors Inc.’s holdings in Johnson & Johnson were worth $5,803,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Briaud Financial Planning Inc boosted its stake in shares of Johnson & Johnson by 4.1% during the 3rd quarter. Briaud Financial Planning Inc now owns 1,281 shares of the company’s stock worth $339,000 after acquiring an additional 50 shares in the last quarter. DUTCH ASSET Corp acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $367,000. Bank Pictet & Cie Europe AG raised its stake in shares of Johnson & Johnson by 6.2% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 9,167 shares of the company’s stock valued at $2,427,000 after acquiring an additional 539 shares in the last quarter. 55 North Private Wealth LLC raised its stake in shares of Johnson & Johnson by 8.0% in the 3rd quarter. 55 North Private Wealth LLC now owns 6,280 shares of the company’s stock valued at $1,663,000 after acquiring an additional 467 shares in the last quarter. Finally, Dagco Inc. raised its stake in shares of Johnson & Johnson by 1.9% in the 3rd quarter. Dagco Inc. now owns 7,112 shares of the company’s stock valued at $1,883,000 after acquiring an additional 132 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Guggenheim restated a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Argus set a $300.00 price target on Johnson & Johnson in a report on Wednesday, July 29th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Finally, Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 64,515 shares of company stock valued at $17,271,766 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive sector rotation: JNJ is benefiting from fresh demand for defensive healthcare stocks, alongside gains in Procter & Gamble and Coca-Cola. Investors appear to be favoring companies with relatively stable demand and cash flows amid broader market pressure. Procter & Gamble Jumps as Defensive Buyers Enter
• Positive Sentiment: Medical-device progress: Johnson & Johnson reported real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its electrophysiology portfolio and provide another growth avenue beyond pharmaceuticals. Johnson & Johnson Reports VARIPULSE and OMNYPULSE Data
• Positive Sentiment: Drug growth and guidance: Recent coverage highlights stronger pharmaceutical performance and Johnson & Johnson’s higher 2026 outlook, with projected sales of approximately $101.2 billion at the midpoint. The company also maintains a 64-year record of annual dividend increases, reinforcing its appeal to income-focused investors. Johnson & Johnson Drugs Lift Guidance
• Neutral Sentiment: Mixed business outlook: One business is advancing strongly while another has stalled, leaving investors focused on whether new growth can justify JNJ’s premium valuation relative to competitors such as Merck and AbbVie. JNJ Stock Has a New Growth Story
• Negative Sentiment: Analyst caution and valuation risk: Erste Group Bank downgraded JNJ from “buy” to “hold.” Commentary also notes that the stock’s elevated valuation could constrain returns, particularly as Treasury yields near 5% make government bonds more competitive with dividend stocks. Erste Group Bank Ratings

Johnson & Johnson Trading Up 3.8%

Shares of NYSE:JNJ opened at $267.67 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock’s 50-day moving average is $265.57 and its 200-day moving average is $250.11. The company has a market cap of $645.05 billion, a P/E ratio of 40.56, a P/E/G ratio of 2.55 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the previous year, the firm earned $2.80 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.